Keywords: pathogenesis, expects, mill, 2nd-qtr, sales, says, report
PathoGenesis expects $20.2 mill 2nd-qtr sales
Article | 07 July 2000
PathoGenesis says that it expects to report $20.2 million insecond-quarter 2000 sales of TOBI (tobramycin for inhalation), an increase of 43% on the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
